Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sarepta Therapeutics Inc's Business Segments
Sarepta Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
All Other Segments
Total Revenue
$ 731
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- All Other Segments100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| All Other Segments | $ 731 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- PMO Products25.8%
- ELEVIDYS14%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| PMO Products | $ 189 | 25.8% |
| ELEVIDYS | $ 102 | 14% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Sarepta Therapeutics Inc
Sarepta Therapeutics Inc is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company is based in Cambridge, Massachusetts, and was founded in 1980.
Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.
The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.
Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.
In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.
Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.
Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.
Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.
The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.
Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.
In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.
Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.
Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.
Sarepta Therapeutics Inc is a pioneering biotechnology company specializing in innovative therapies for rare genetic and neuromuscular diseases. The company’s commitment to addressing severe, often life-threatening conditions through cutting-edge science has resulted in a diverse portfolio of segments, products, and services. Below is an extensive overview of the companys offerings, organized into four main segments:
1. Therapeutic Products
Sarepta Therapeutics is primarily recognized for its portfolio of therapeutic products targeting rare diseases, particularly neuromuscular disorders.
- Exondys 51 (eteplirsen): As the flagship product, Exondys 51 is an RNA-targeted therapy specifically developed for Duchenne muscular dystrophy (DMD)—a severe genetic disorder characterized by progressive muscle degeneration. This innovative drug utilizes the mechanism of exon skipping to allow the production of a truncated but functional dystrophin protein, crucial for muscle health.
- Other RNA-based Therapies: Beyond Exondys 51, Sarepta is advancing a series of additional RNA-targeted therapies aimed at various forms of muscular dystrophies and related conditions:
- Golodirsen: Another exon-skipping therapy under development for patients with DMD lacking a specific exon.
- Viltolarsen: A therapeutic candidate being investigated for its ability to modify the dystrophin gene in a similar fashion.
- Therapies for Limb-girdle Muscular Dystrophy (LGMD): Sarepta is exploring RNA-based approaches to treat LGMD, a group of genetic disorders affecting the proximal muscles of the body.
- Pompe Disease and Charcot-Marie-Tooth Disease (CMT): Ongoing projects seek to develop effective therapies targeting these rare genetic disorders as well.
Gene Therapy
In addition to RNA-targeted solutions, Sarepta Therapeutics is at the forefront of gene therapy research, leveraging advanced gene delivery technologies.
- Adeno-Associated Virus (AAV) Platform: This platform enables the introduction of therapeutic genes directly into a patients cells using modified viruses, thereby offering a potential one-time treatment solution for genetic disorders.
- Focus on DMD and Other Neuromuscular Diseases: The company is developing several gene therapy candidates aimed at both DMD and other conditions, including:
- SRP-9001: This gene therapy aims to deliver a micro-dystrophin gene, which is a shortened but functional version of dystrophin, to optimize muscle function in DMD patients.
- Early-Stage Development Candidates: Various pipeline candidates are being explored for other neuromuscular disorders, making use of the AAV technology to tackle genetic mutations.
Companion Diagnostics
Sarepta Therapeutics also recognizes the importance of personalized medicine through the development of companion diagnostics.
- Identifying Suitable Candidates: These diagnostics are designed to identify patients who are most likely to benefit from specific RNA-based and gene therapies. By understanding the genetic makeup of the patient population, Sarepta can streamline the treatment process and improve overall patient outcomes.
- Biomarkers for Disease Monitoring: In conjunction with their therapeutic advancements, the company is engaged in developing biomarkers that can effectively monitor disease progression and the patient’s response to treatment.
Contract Manufacturing Services
In addition to its therapeutic focus, Sarepta Therapeutics offers contract manufacturing services that leverage its extensive expertise in biologics.
- Development and Manufacturing: These services include process development for RNA and gene therapies, as well as clinical and commercial manufacturing to support other biotechnology and pharmaceutical companies.
- Quality Control and Assurance: Sarepta ensures that all contract manufacturing processes adhere to stringent quality control standards, thus reinforcing its reputation as a leader in the field of gene and RNA therapeutics.
Conclusion
Sarepta Therapeutics Inc continues to be a leader in the realm of innovative therapies for rare and serious diseases. Through its diversified portfolio, which encompasses therapeutic products, gene therapies, companion diagnostics, and contract manufacturing services, the company is uniquely positioned to address unmet medical needs while setting new standards in the treatment of genetic disorders. The integration of cutting-edge scientific advancements into their offerings reflects a profound commitment to improving the lives of patients affected by devastating conditions such as DMD and beyond.
1. Therapeutic Products
Sarepta Therapeutics is primarily recognized for its portfolio of therapeutic products targeting rare diseases, particularly neuromuscular disorders.
- Exondys 51 (eteplirsen): As the flagship product, Exondys 51 is an RNA-targeted therapy specifically developed for Duchenne muscular dystrophy (DMD)—a severe genetic disorder characterized by progressive muscle degeneration. This innovative drug utilizes the mechanism of exon skipping to allow the production of a truncated but functional dystrophin protein, crucial for muscle health.
- Other RNA-based Therapies: Beyond Exondys 51, Sarepta is advancing a series of additional RNA-targeted therapies aimed at various forms of muscular dystrophies and related conditions:
- Golodirsen: Another exon-skipping therapy under development for patients with DMD lacking a specific exon.
- Viltolarsen: A therapeutic candidate being investigated for its ability to modify the dystrophin gene in a similar fashion.
- Therapies for Limb-girdle Muscular Dystrophy (LGMD): Sarepta is exploring RNA-based approaches to treat LGMD, a group of genetic disorders affecting the proximal muscles of the body.
- Pompe Disease and Charcot-Marie-Tooth Disease (CMT): Ongoing projects seek to develop effective therapies targeting these rare genetic disorders as well.
Gene Therapy
In addition to RNA-targeted solutions, Sarepta Therapeutics is at the forefront of gene therapy research, leveraging advanced gene delivery technologies.
- Adeno-Associated Virus (AAV) Platform: This platform enables the introduction of therapeutic genes directly into a patients cells using modified viruses, thereby offering a potential one-time treatment solution for genetic disorders.
- Focus on DMD and Other Neuromuscular Diseases: The company is developing several gene therapy candidates aimed at both DMD and other conditions, including:
- SRP-9001: This gene therapy aims to deliver a micro-dystrophin gene, which is a shortened but functional version of dystrophin, to optimize muscle function in DMD patients.
- Early-Stage Development Candidates: Various pipeline candidates are being explored for other neuromuscular disorders, making use of the AAV technology to tackle genetic mutations.
Companion Diagnostics
Sarepta Therapeutics also recognizes the importance of personalized medicine through the development of companion diagnostics.
- Identifying Suitable Candidates: These diagnostics are designed to identify patients who are most likely to benefit from specific RNA-based and gene therapies. By understanding the genetic makeup of the patient population, Sarepta can streamline the treatment process and improve overall patient outcomes.
- Biomarkers for Disease Monitoring: In conjunction with their therapeutic advancements, the company is engaged in developing biomarkers that can effectively monitor disease progression and the patient’s response to treatment.
Contract Manufacturing Services
In addition to its therapeutic focus, Sarepta Therapeutics offers contract manufacturing services that leverage its extensive expertise in biologics.
- Development and Manufacturing: These services include process development for RNA and gene therapies, as well as clinical and commercial manufacturing to support other biotechnology and pharmaceutical companies.
- Quality Control and Assurance: Sarepta ensures that all contract manufacturing processes adhere to stringent quality control standards, thus reinforcing its reputation as a leader in the field of gene and RNA therapeutics.
Conclusion
Sarepta Therapeutics Inc continues to be a leader in the realm of innovative therapies for rare and serious diseases. Through its diversified portfolio, which encompasses therapeutic products, gene therapies, companion diagnostics, and contract manufacturing services, the company is uniquely positioned to address unmet medical needs while setting new standards in the treatment of genetic disorders. The integration of cutting-edge scientific advancements into their offerings reflects a profound commitment to improving the lives of patients affected by devastating conditions such as DMD and beyond.